• Home
• Responsibility
• CR Report 2004
• Caring for the environment
• Ozone depletion
• Ozone depleting substances in manufacturing

Ozone depleting substances in manufacturing

A small proportion of the CFC used to manufacture Metered Dose Inhalers (MDIs) is released during the manufacturing process. We are working to eliminate use of ozone depleting substances (ODSs) in MDIs by switching to HFC and dry powder inhalers (see metered dose inhalers).

Year	Production
	(million kg)
2001	0.183
2002	0.121
2003	0.072
2004	0.059

Per unit sales as percentage of 2001 baseline
2001	2002	2003	2004	2005
100%	63.8%	37.4%	32.5%	50.0%

Ozone depleting substances released from production activities
Substance	2002	2003	2004
CFC11/R11	12,634	1.0	12,634
CFC12/R12	46,304	1.0	46,304
1,1,1 TRICHLOROETHANE	265	0.1	27
METHYL BROMIDE	590	0.6	354

	2001	2002	2003	2004
	(thousand kg CFC-11 equivalent)
01. R&D	0.00	0.00	0.00	0.00
02. Biologicals	0.00	0.00	0.00	0.00
03. Consumer healthcare	0.00	0.00	0.00	0.00
04. New product and global supply	111.87	74.59	42.35	47.36
05. Regional pharma supply	70.53	46.19	29.15	11.61
06. Primary supply and antibiotics	0.00	0.50	0.40	0.35
07. Commercial	0.00	0.00	0.00	0.00
08. Other	1.09	0.00	0.00	0.00

Total ozone depletion potential from production decreased by 18.1% since 2003 (67.8% since 2001). Ozone depletion potential from production per unit sales decreased by 13.1% since 2003 (67.5% since 2001) - meaning we have exceeded our 2005 target of a 50% reduction per unit sales since 2001.

As production of CFC-containing MDIs decreases, the amount of CFC lost during production also declines. We will no longer manufacture CFC-containing MDIs in the US after 2005 and in Europe after 2006. We will continue to manufacture them in Bangladesh, China, India and Pakistan until the end of 2009.

Back to top